Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06993181

Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects

This study is to compare pharmacokinetics and safety profiles of DA-5222 single-administration and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Healthy

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Bumin Hospital

Seoul, South Korea, 07590

Location contact

Taegon Hong, Ph.D

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers
  • BMI between 18 and 30 kg/m2
  • Body weight: Male≥50kg, Female≥45kg
  • Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study

Exclusion criteria

  • Subjects with clinically significant medical history
  • Subjects with history of drug abuse or addicted
  • Subjects with allergy or drug hypersensitivity

Treatment and study plan

DA-5222

Drug

single dose administration (DA-5222 one tablet once a day)

DA-5222-R1

Drug

single dose administration (DA-5222-R1 one tablet once a day)

DA-5222-R2

Drug

single dose administration (DA-5222-R2 one tablet once a day)

DA-5222-R3

Drug

single dose administration (DA-5222-R3 one tablet once a day)

Primary outcomes

  1. AUCt

    Time frame: pre-dose~72 hours post-dose

    area under the curve

  2. Cmax

    Time frame: pre-dose~72 hours post-dose

    maximum plasma concentration

Study contacts

Contact information is provided by the study sponsor or research team.

Heechan Jung

CONTACT

[email protected]

+82-02-920-8322

Jihyun Sung

CONTACT

[email protected]

+82-02-920-8369

Sponsors and collaborators

Lead sponsor

Dong-A ST Co., Ltd.

Industry

Registry information

Official study title

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
May 28, 2025
Registry last updated
Jun 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.